Muriel Barberi-Heyob

List of Publications by Year
in descending order

58 papers	3,274 citations	159585 30 h-index	149698 56 g-index
58 all docs	58 docs citations	58 times ranked	4977 citing authors

#	Article	IF	Citations
1	Multi-tracer and multiparametric PET imaging to detect the IDH mutation in glioma: a preclinical translational in vitro, in vivo, and ex vivo study. Cancer Imaging, 2022, 22, 16.	2.8	5
2	Can Cerenkov Light Really Induce an Effective Photodynamic Therapy?. Radiation, 2021, 1, 5-17.	1.4	11
3	In vivo characterization of physiological and metabolic changes related to isocitrate dehydrogenase 1 mutation expcression by multiparametric MRI and MRS in a rat model with orthotopically grafted humanâ€derived glioblastoma cell lines. NMR in Biomedicine, 2021, 34, e4490.	2.8	5
4	Terbium-Based AGuIX-Design Nanoparticle to Mediate X-ray-Induced Photodynamic Therapy. Pharmaceuticals, 2021, 14, 396.	3.8	3
5	The detrimental invasiveness of glioma cells controlled by gadolinium chelate-coated gold nanoparticles. Nanoscale, 2021, 13, 9236-9251.	5.6	7
6	Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography. Molecules, 2021, 26, 7273.	3.8	4
7	Multiscale Selectivity and in vivo Biodistribution of NRP-1-Targeted Theranostic AGuIX Nanoparticles for PDT of Glioblastoma . International Journal of Nanomedicine, 2020, Volume 15, 8739-8758.	6.7	19
8	Overcoming the diverse mechanisms of multidrug resistance in lung cancer cells by photodynamic therapy using pTHPP-loaded PLGA-lipid hybrid nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 149, 218-228.	4.3	27
9	AGuIX^{Â®} from bench to bedsideâ€"Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. British Journal of Radiology, 2019, 92, 20180365.	2.2	86
10	Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment. Advanced Drug Delivery Reviews, 2019, 138, 344-357.	13.7	90
11	Stimulation of medulloblastoma stem cells differentiation by a peptidomimetic targeting neuropilin-1. Oncotarget, 2018, 9, 15312-15325.	1.8	22
12	Molecular modelling, synthesis and biological evaluation of peptide inhibitors as anti-angiogenic agent targeting neuropilin-1 for anticancer application. Journal of Biomolecular Structure and Dynamics, 2017, 35, 26-45.	3.5	22
13	Polymer-lipid-PEG hybrid nanoparticles as photosensitizer carrier for photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology, 2017, 173, 12-22.	3.8	34
14	Proton MR Spectroscopy and Diffusion MR Imaging Monitoring to Predict Tumor Response to Interstitial Photodynamic Therapy for Glioblastoma. Theranostics, 2017, 7, 436-451.	10.0	29
15	Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma. International Journal of Nanomedicine, 2017, Volume 12, 7075-7088.	6.7	39
16	Monte Carlo simulations guided by imaging to predict the in vitro ranking of radiosensitizing nanoparticles. International Journal of Nanomedicine, 2016, Volume 11, 6169-6179.	6.7	11
17	Carbohydrate-based peptidomimetics targeting neuropilin-1: Synthesis, molecular docking study and in vitro biological activities. Bioorganic and Medicinal Chemistry, 2016, 24, 5315-5325.	3.0	29
18	Robustness Analysis of a Geant4-GATE Simulator for Nanoradiosensitizers Characterization. IEEE Transactions on Nanobioscience, 2016, 15, 209-217.	3.3	6

#	Article	IF	Citations
19	New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy. International Journal of Molecular Sciences, 2015, 16, 24059-24080.	4.1	29
20	Nanoparticles for Radiation Therapy Enhancement: the Key Parameters. Theranostics, 2015, 5, 1030-1044.	10.0	289
21	Multifunctional ultrasmall nanoplatforms for vascular-targeted interstitial photodynamic therapy of brain tumors guided by real-time MRI. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 657-670.	3.3	52
22	How Nanoparticles Can Solve Resistance and Limitation in PDT Efficiency. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 197-211.	0.1	3
23	Preparation and characterization of mTHPC-loaded solid lipid nanoparticles for photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology, 2014, 130, 161-169.	3.8	41
24	Rational design of an arene ruthenium chlorin conjugate for in vivo anticancer activity. Inorganica Chimica Acta, 2014, 414, 134-140.	2.4	15
25	X-ray-Induced Singlet Oxygen Activation with Nanoscintillator-Coupled Porphyrins. Journal of Physical Chemistry C, 2013, 117, 21583-21589.	3.1	117
26	Bifunctional polypyridyl-Ru(ii) complex grafted onto gadolinium-based nanoparticles for MR-imaging and photodynamic therapy. Dalton Transactions, 2013, 42, 12410.	3.3	32
27	Global sensitivity analysis and estimation of photophysical parameters from in vivo data in photodynamic therapy. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2012, 45, 1731-1736.	0.4	1
28	System identification of the intrabrain tumoral uptake of multifunctional nanoparticles. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2012, 45, 154-159.	0.4	1
29	Systems biology approach for in vivo photodynamic therapy optimization of ruthenium-porphyrin compounds. Journal of Photochemistry and Photobiology B: Biology, 2012, 117, 80-89.	3.8	51
30	Tumor vascular responses to antivascular and antiangiogenic strategies: looking for suitable models. Trends in Biotechnology, 2012, 30, 649-658.	9.3	14
31	Multifunctional Peptide-Conjugated Hybrid Silica Nanoparticles for Photodynamic Therapy and MRI. Theranostics, 2012, 2, 889-904.	10.0	75
32	Real-Time Monitoring of Photocytotoxicity in Nanoparticles-Based Photodynamic Therapy: A Model-Based Approach. PLoS ONE, 2012, 7, e48617.	2.5	19
33	Stability of peptides and therapeutic success in cancer. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 793-802.	3.3	46
34	Quantum dotâ€"folic acid conjugates as potential photosensitizers in photodynamic therapy of cancer. Photochemical and Photobiological Sciences, 2011, 10, 842.	2.9	55
35	Functionalized silica-based nanoparticles for photodynamic therapy. Nanomedicine, 2011, 6, 995-1009.	3.3	30
36	Nanoparticles for Photodynamic Therapy Applications. Fundamental Biomedical Technologies, 2011, , 511-565.	0.2	8

#	Article	IF	Citations
37	Neuropilin-1 Targeting Photosensitization-Induced Early Stages of Thrombosis via Tissue Factor Release. Pharmaceutical Research, 2010, 27, 468-479.	3.5	35
38	Photodynamic therapy targeting neuropilin-1: Interest of pseudopeptides with improved stability properties. Biochemical Pharmacology, 2010, 80, 226-235.	4.4	38
39	Sugar-based peptidomimetics as potential inhibitors of the vascular endothelium growth factor binding to neuropilin-1. Bioorganic and Medicinal Chemistry, 2010, 18, 3285-3298.	3.0	35
40	Peptide-conjugated chlorin-type photosensitizer binds neuropilin-1 in vitro and in vivo. Journal of Photochemistry and Photobiology B: Biology, 2009, 96, 101-108.	3.8	35
41	Response Surface Methodology: An Extensive Potential to Optimize in vivo Photodynamic Therapy Conditions. International Journal of Radiation Oncology Biology Physics, 2009, 75, 244-252.	0.8	29
42	Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends in Biotechnology, 2008, 26, 612-621.	9.3	692
43	Tissue distribution and pharmacokinetics of an ATWLPPR-conjugated chlorin-type photosensitizer targeting neuropilin-1 in glioma-bearing nude mice. Photochemical and Photobiological Sciences, 2008, 7, 433-441.	2.9	39
44	Improvement of<i>meta</i>-tetra(Hydroxyphenyl)chlorin-Like Photosensitizer Selectivity with Folate-Based Targeted Delivery. Synthesis and in Vivo Delivery Studies. Journal of Medicinal Chemistry, 2008, 51, 3867-3877.	6.4	112
45	Identification of Pharmacokinetics Models in the Presence of Timing Noise. European Journal of Control, 2008, 14, 149-157.	2.6	5
46	System identification of the intracellular photoreaction process induced by photodynamic therapy. , 2008, , .		4
47	Advantages and limitations of commonly used methods to assay the molecular permeability of gap junctional intercellular communication. BioTechniques, 2008, 45, 33-62.	1.8	102
48	Phthalocyanines Covalently Bound to Biomolecules for a Targeted Photodynamic Therapy. Current Medicinal Chemistry, 2007, 14, 1673-1687.	2.4	156
49	Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity. Bioorganic Chemistry, 2007, 35, 205-220.	4.1	74
50	Gap junctional intercellular communication capacity by gap-FRAP technique: A comparative study. Biotechnology Journal, 2007, 2, 50-61.	3.5	61
51	Metabolic Profile of a Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1: An in Vivo and in Vitro Study. Drug Metabolism and Disposition, 2007, 35, 806-813.	3.3	36
52	Divergent synthesis of novel unsymmetrical dendrons containing photosensitizing units. Tetrahedron Letters, 2006, 47, 8745-8749.	1.4	3
53	A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. Journal of Controlled Release, 2006, 111, 153-164.	9.9	135
54	Recent Improvements in the Use of Synthetic Peptides for a Selective Photodynamic Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2006, 6, 469-488.	1.7	52

#	Article	IF	Citations
55	Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy. Bioorganic and Medicinal Chemistry, 2005, 13, 2799-2808.	3.0	188
56	The 2-aminoglucosamide motif improves cellular uptake and photodynamic activity of tetraphenylporphyrin. European Journal of Medicinal Chemistry, 2005, 40, 1111-1122.	5.5	63
57	Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. International Journal of Radiation Oncology Biology Physics, 2004, 59, 250-259.	0.8	52
58	Vascular-Targeted Photodynamic Therapy (VTP). , 0, , .		1